Analysts Set AC Immune (NASDAQ:ACIU) PT at $7.50

AC Immune (NASDAQ:ACIU) has been given an average recommendation of “Hold” by the five ratings firms that are covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and three have issued a buy recommendation on the company. The average twelve-month price target among analysts that have updated their coverage on the stock in the last year is $7.50.

Several equities analysts have commented on the stock. HC Wainwright reissued a “buy” rating on shares of AC Immune in a research report on Monday. BTIG Research reaffirmed a “buy” rating and issued a $8.00 price target on shares of AC Immune in a research report on Thursday, August 20th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of AC Immune in a research note on Wednesday, August 5th.

Hedge Funds Weigh In On AC Immune

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. AXQ Capital LP bought a new position in shares of AC Immune in the second quarter valued at approximately $25,000. EFG International AG bought a new stake in shares of AC Immune during the 4th quarter worth $41,000. Private Advisor Group LLC bought a new stake in shares of AC Immune during the 3rd quarter worth $48,000. Sei Investments Co. acquired a new position in AC Immune in the 2nd quarter valued at $51,000. Finally, Goldman Sachs Group Inc. grew its stake in AC Immune by 46.9% in the 4th quarter. Goldman Sachs Group Inc. now owns 18,555 shares of the company’s stock valued at $58,000 after buying an additional 5,920 shares during the last quarter. Institutional investors and hedge funds own 51.36% of the company’s stock.

AC Immune Trading Down 2.4%

Shares of NASDAQ ACIU opened at $2.85 on Thursday. The stock has a market cap of $290.04 million, a price-to-earnings ratio of -5.28 and a beta of 1.59. The business has a 50 day simple moving average of $2.45 and a 200 day simple moving average of $2.69. The company has a debt-to-equity ratio of 0.11, a quick ratio of 1.02 and a current ratio of 0.93. AC Immune has a 52 week low of $2.03 and a 52 week high of $4.00.

AC Immune (NASDAQ:ACIU) last announced its quarterly earnings results on Thursday, August 6th. The company reported $0.03 EPS for the quarter, topping the consensus estimate of ($0.10) by $0.13. AC Immune had a negative net margin of 245.32% and a negative return on equity of 100.17%. The company had revenue of $18.67 million for the quarter, compared to analyst estimates of $9.59 million. On average, research analysts predict that AC Immune will post -0.6 earnings per share for the current fiscal year.

About AC Immune

AC Immune AG is a clinical-stage biopharmaceutical company headquartered in Lausanne, Switzerland, with a subsidiary in Boston, Massachusetts. The company specializes in the discovery and development of therapeutics and diagnostics for neurodegenerative diseases, with a primary focus on Alzheimer’s disease, Parkinson’s disease and other protein misfolding disorders. AC Immune leverages proprietary platform technologies to identify and optimize candidates that target pathological protein aggregates.

Since its founding in 2003, AC Immune has advanced multiple programs into clinical development.